new all time high, page-8

I should add that if only last years EPS growth is used then the results is under $12. So I guess the question from a valuation point of view is whether this last years growth is an anomaly or is the new standard for SRX.

As the dose sales and revenue held up reasonably well, then I must assume that the CFO lost a little control on the expenditure - marketing is the killer currently and well above the % numbers compared to Resmed and Cochlear.

Thus, IMO it was an anomaly, and greater EPS growth will return. Following are the consensus numbers going forward.

Next 3 years are estimated EPS growth of 33%, 10% (?), 39%, or an average of 24% compound. Wind the clock forward to next year and assume the EPS of 42c is achieved, then the formula would yield $27. Fairy dust or reasonable - only time will tell, and there are risks out there for sure.

We should get the current 1/4 dose numbers in 3 weeks time so will have another clue as to where things are going. Anything less than 20% would be a worry - IMO.